0000000000263599

AUTHOR

Alexandre Mebazaa

0000-0001-8715-7753

showing 3 related works from this author

Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF

2020

Aims: \ud This retrospective analysis sought to identify markers that might distinguish between acute heart failure (HF) and worsening HF in chronic outpatients.\ud \ud Methods and Results: \ud The BIOSTAT‐CHF index cohort included 2516 patients with new or worsening HF symptoms: 1694 enrolled as inpatients (acute HF) and 822 as outpatients (worsening HF in chronic outpatients). A validation cohort included 935 inpatients and 803 outpatients. Multivariable models were developed in the index cohort using clinical characteristics, routine laboratory values, and proteomics data to examine which factors predict adverse outcomes in both conditions and to determine which factors differ between ac…

medicine.medical_specialtyAdverse outcomesacute heart failure treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemacute heart failure diagnosisInternal medicineOutpatientsDiagnosismedicineRetrospective analysisHumansAcute heart failure; acute heart failure diagnosis; acute heart failure treatmentRetrospective StudiesHeart Failurebusiness.industryTreatment developmentRoutine laboratoryAcute heart failurePrognosismedicine.diseaseR1[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHospitalizationTreatmentHeart failureChronic DiseaseCohortBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessCarbohydrate antigen
researchProduct

Impact of Midregional N‐Terminal Pro–Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treate…

2021

Background We assessed the impact of preprocedural plasma levels of MRproANP (midregional N‐terminal pro–atrial natriuretic peptide) and sST2 (soluble suppression of tumorigenicity 2) on recurrence of atrial fibrillation (AF) at 1 year after catheter ablation of AF. Methods and Results This was a prospective, multicenter, observational study including patients undergoing catheter ablation of AF. MRproANP and sST2 were measured in a peripheral venous blood preprocedure, and MRproANP was assessed in the right and left atrial blood during ablation. The primary end point was recurrent AF between 3 and 12 months postablation, defined as a documented (>30 seconds) episode of AF, flutter, or a…

Malemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentBiorhythmCatheter ablation030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineHeart RatePredictive Value of TestsRecurrenceRisk FactorsInternal medicinecatheter ablationAtrial FibrillationmedicineNatriuretic peptideHumansIn patientArrhythmia and Electrophysiology030212 general & internal medicineHeart AtriaProspective StudiesOriginal ResearchAgedsST2business.industryMRproANPbiomarkersAtrial fibrillationPlasma levelsMiddle Agedmedicine.diseaseInterleukin-1 Receptor-Like 1 ProteinUp-RegulationHeart RhythmTreatment OutcomePro atrial natriuretic peptideCardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessCatheter Ablation and Implantable Cardioverter-DefibrillatorAtrial Natriuretic FactorJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
researchProduct

Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction

2018

IF 16.834 (2017); International audience; BACKGROUND Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking. OBJECTIVES The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction. METHODS The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was…

MaleInotropeILL PATIENTSCardiac index030204 cardiovascular system & hematologyLACTATE0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesSUPPORTTISSUE OXYGENATIONVasoconstrictor AgentsProspective StudiesMyocardial infarctionCardiogenic shockcardiogenic shockMiddle Aged3. Good healthEpinephrineCardiologyHEARTFemaleTRIALFranceCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyShock Cardiogenicacute myocardial infarctionvasopressornorepinephrineEXTRACORPOREAL MEMBRANE-OXYGENATIONNorepinephrine (medication)03 medical and health sciencesDouble-Blind MethodInternal medicineHeart rateMANAGEMENTmedicineHumansepinephrineAgedbusiness.industrySeptic shockMORTALITYSEPTIC SHOCKHemodynamics030208 emergency & critical care medicinemedicine.disease3121 General medicine internal medicine and other clinical medicinebusiness
researchProduct